Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 857,165
  • Shares Outstanding, K 54,701
  • Annual Sales, $ 0 K
  • Annual Income, $ -103,230 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.72
  • Number of Estimates 2
  • High Estimate -0.70
  • Low Estimate -0.74
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +25.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.00 +11.93%
on 05/02/19
16.97 -7.66%
on 05/21/19
+0.38 (+2.49%)
since 04/24/19
3-Month
14.00 +11.93%
on 05/02/19
21.50 -27.12%
on 04/05/19
-1.95 (-11.07%)
since 02/22/19
52-Week
13.04 +20.17%
on 07/27/18
32.88 -52.34%
on 09/20/18
-3.80 (-19.52%)
since 05/24/18

Most Recent Stories

More News
Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 15.67 (+3.91%)
Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 15.67 (+3.91%)
New Research Coverage Highlights Kiniksa Pharmaceuticals, Ryerson Holding, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Synthetic Biologics -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kiniksa Pharmaceuticals, Ltd....

KNSA : 15.67 (+3.91%)
RYI : 9.09 (-1.84%)
SYN : 0.54 (-2.07%)
OMAB : 49.12 (-1.58%)
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

- First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis

KNSA : 15.67 (+3.91%)
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 15.67 (+3.91%)
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology's 68th Annual Scientific Session

- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period

KNSA : 15.67 (+3.91%)
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity

- Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial

KNSA : 15.67 (+3.91%)
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39 Annual Healthcare Conference on Wednesday, March 13 at 8:00 a.m. Eastern Time at The Boston...

KNSA : 15.67 (+3.91%)
Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2019 at 8:30 a.m. Eastern Time at the Loews Miami Beach...

KNSA : 15.67 (+3.91%)
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa", "we", and "our") announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per...

KNSA : 15.67 (+3.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade KNSA with:

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 16.10
1st Resistance Point 15.89
Last Price 15.67
1st Support Level 15.29
2nd Support Level 14.90

See More

52-Week High 32.88
Fibonacci 61.8% 25.30
Fibonacci 50% 22.96
Fibonacci 38.2% 20.62
Last Price 15.67
52-Week Low 13.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar